Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Default user image.

Linda Knutsson

Professor

Default user image.

The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma

Författare

  • Xiang Xu
  • Jiadi Xu
  • Linda Knutsson
  • Jing Liu
  • Huanling Liu
  • Yuguo Li
  • Bachchu Lal
  • John Laterra
  • Dmitri Artemov
  • Guanshu Liu
  • Peter C.M. van Zijl
  • Kannie W.Y. Chan
Visa allt

Summary, in English

Purpose: The mammalian target of rapamycin is an enzyme that regulates cell metabolism and proliferation. It is up-regulated in aggressive tumors, such as glioblastoma, leading to increased glucose uptake and consumption. It has been suggested that glucose CEST signals reflect the delivery and tumor uptake of glucose. The inhibitor rapamycin (sirolimus) has been applied as a glucose deprivation treatment; thus, glucose CEST MRI could potentially be useful for monitoring the tumor responses to inhibitor treatment. Methods: A human U87-EGFRvIII xenograft model in mice was studied. The mice were treated with a mammalian target of Rapamycin inhibitor, rapamycin. The effect of the treatment was evaluated in vivo with dynamic glucose CEST MRI. Results: Rapamycin treatment led to significant increases (P < 0.001) in dynamic glucose-enhanced signal in both the tumor and contralateral brain as compared to the no-treatment group, namely a maximum enhancement of 3.7% ± 2.3% (tumor, treatment) versus 1.9% ± 0.4% (tumor, no-treatment), 1.7% ± 1.1% (contralateral, treatment), and 1.0% ± 0.4% (contralateral, no treatment). Dynamic glucose-enhanced contrast remained consistently higher in treatment versus no-treatment groups for the duration of the experiment (17 min). This was confirmed with area-under-curve analysis. Conclusion: Increased glucose CEST signal was found after mammalian target of Rapamycin inhibition treatment, indicating potential for dynamic glucose-enhanced MRI to study tumor response to glucose deprivation treatment.

Avdelning/ar

  • Medicinsk strålningsfysik, Lund
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
  • MR Physics

Publiceringsår

2019-02-22

Språk

Engelska

Sidor

3798-3807

Publikation/Tidskrift/Serie

Magnetic Resonance in Medicine

Volym

81

Issue

6

Dokumenttyp

Artikel i tidskrift

Förlag

John Wiley & Sons Inc.

Ämne

  • Cancer and Oncology
  • Radiology, Nuclear Medicine and Medical Imaging
  • Other Physics Topics

Nyckelord

  • DGE MRI
  • glioblastoma
  • glucoCEST
  • mTOR inhibitor
  • preclinical imaging
  • rapamycin

Status

Published

Projekt

  • Natural sugar as an MRI contrast agent for cancer diagnosis

Forskningsgrupp

  • MR Physics

ISBN/ISSN/Övrigt

  • ISSN: 0740-3194